Latest Breaking News On - Ono pharmaceutical - Page 12 : comparemela.com

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesBristol myers squibbAmy petersonDana walkerBristol myersMyers squibbAmerican societyClinical oncology genitourinary cancers symposiumOno pharmaceutical

Bristol Myers Squibb - Eight-Year Data for Opdivo Plus Yervoy Continue to Demonstrate Longest Survival Benefit vs Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

PRINCETON - Bristol Myers Squibb today announced that Opdivo plus Yervoy continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28%.

United statesSouth koreaNizar tannirDana walkerBristol myers squibbDrug administrationDivision of cancer medicineCompany opdivoEuropean unionUniversity of texasInternational metastaticMd anderson cancer centerExchange commissionDepartment of genitourinary medical oncologyAmerican society of clinical oncologyDatabase consortium

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Opdivo in combination with CABOMETYX reduced the risk of death by 23% in the first-line treatment of advanced renal cell carcinoma vs. sunitinib Four-year results demonstrating continued benefits.

United statesSouth koreaDana walkerAmy petersonBristol myers squibbMaria teresa bourlonInternational metastatic renal cell carcinoma database consortiumTakeda pharmaceutical companyExelixis incCompany opdivoAmerican society of clinical oncologyExchange commissionEuropean unionOno pharmaceutical coAmerican societyClinical oncology

Lilly s Jaypirca tipped to capture 60% of BTK leukemia market, leaving AstraZeneca, BeiGene in the dust

Lilly s Jaypirca tipped to capture 60% of BTK leukemia market, leaving AstraZeneca, BeiGene in the dust
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Beigene brukinsaAstrazeneca calquenceEli lillyMerck coInflation reduction actLoxo oncologyOno pharmaceutical

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaBristol myers squibbDana walkerAmy petersonMaria teresa bourlonProduct serviceExchange commissionExelixis incEuropean unionTakeda pharmaceutical companyCompany opdivoInternational metastatic renal cell carcinoma database consortiumAmerican society of clinical oncologyOno pharmaceutical coFirst line advanced renal cell